VRTX Jan 2024 410.000 call
| Previous close | 1.5000 |
| Open | 1.6000 |
| Bid | 0.4000 |
| Ask | 2.7500 |
| Strike | 410.00 |
| Expiry date | 2024-01-19 |
| Day's range | 1.6000 - 1.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 331 |
Motley Fool5 Top Stocks to Buy Before 2024
One area to focus on is companies that generally offer steady earnings growth over time. CRISPR Therapeutics (NASDAQ: CRSP) just reached a huge milestone, and another may be just ahead. The company recently won the world's first authorization for a CRISPR-based gene-editing treatment when the U.K. gave the nod to exa-cel (to be commercialized as Casgevy).
Motley FoolCould CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Biotech companies CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) are often mentioned in the same sentence. Vertex is a much larger company with proven innovative abilities, and it has generated strong and consistent revenue, earnings, and stock-market performance in the past decade. CRISPR is a much younger company with a much shorter track record, but could it one day become as successful as its larger partner?
ZacksArcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up
Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.
